Research Papers:

HER2 as a novel therapeutic target for cervical cancer

Doo-Yi Oh, Seokhwi Kim, Yoon-La Choi, Young Jae Cho, Ensel Oh, Jung-Joo Choi, Kyungsoo Jung, Ji-Young Song, Suzie E. Ahn, Byoung-Gie Kim, Duk-Soo Bae, Woong-Yang Park, Jeong-Won Lee _ and Sangyong Song

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2015; 6:36219-36230. https://doi.org/10.18632/oncotarget.5283

Metrics: PDF 2715 views  |   HTML 3010 views  |   ?  


Doo-Yi Oh1,2,3,*, Seokhwi Kim1,*, Yoon-La Choi1,2,3,*, Young Jae Cho4,*, Ensel Oh2,3, Jung-Joo Choi4, Kyungsoo Jung3, Ji-Young Song2, Suzie E. Ahn2, Byoung-Gie Kim4, Duk-Soo Bae4, Woong-Yang Park3,5, Jeong-Won Lee2,3,4,*, Sangyong Song1,2,*

1Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

2Institute for Refractory Cancer Research, Samsung Medical Center, Seoul, Korea

3Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea

4Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

5Samsung Genome Institute, Samsung Medical Center, Seoul, Korea

*These authors have contributed equally to this work

Correspondence to:

Jeong-Won Lee, e-mail: [email protected]

Sangyong Song, e-mail: [email protected]

Keywords: HER2, cervical cancer, targeted therapy, patient-derived xenograft, trastuzumab

Received: June 09, 2015     Accepted: September 11, 2015     Published: September 21, 2015


Surgery and radiation are the current standard treatments for cervical cancer. However, there is no effective therapy for metastatic or recurrent cases, necessitating the identification of therapeutic targets. In order to create preclinical models for screening potential therapeutic targets, we established 14 patient-derived xenograft (PDX) models of cervical cancers using subrenal implantation methods. Serially passaged PDX tumors retained the histopathologic and genomic features of the original tumors. Among the 9 molecularly profiled cervical cancer patient samples, a HER2-amplified tumor was detected by array comparative genomic hybridization and targeted next-generation sequencing. We confirmed HER2 overexpression in the tumor and serially passaged PDX. Co-administration of trastuzumab and lapatinib in the HER2-overexpressed PDX significantly inhibited tumor growth compared to the control. Thus, we established histopathologically and genomically homologous PDX models of cervical cancer using subrenal implantation. Furthermore, we propose HER2 inhibitor-based therapy for HER2-amplified cervical cancer refractory to conventional therapy.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5283